Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Contemporary Clinical Trials|March 6, 2018
Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysisKan Li, Shuai Sammy Yuan, William Wang, et al.
Pharmaceutical Statistics|August 24, 2017
Control-based imputation for sensitivity analyses in informative censoring for recurrent event dataFei Gao, Guanghan F Liu, Donglin Zeng, et al.
Journal of Biomolecular Screening|April 17, 2007
The use of strictly standardized mean difference for hit selection in primary RNA interference high-throughput screening experimentsXiaohua Douglas Zhang, Marc Ferrer, Amy S Espeseth, et al.
The Pediatric Infectious Disease Journal|June 22, 2002
Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infectionShu Li, Ivan S F Chan, Holly Matthews, et al.
The New England Journal of Medicine|May 28, 2016
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical PatientsAlexander T Cohen, Robert A Harrington, Samuel Z Goldhaber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2004
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudinePaul M Coplan, John R Cook, George W Carides, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III studyCharles L Vogel, Marek Z Wojtukiewicz, Robert R Carroll, et al.
Journal of Biomolecular Screening|September 21, 2010
The use of SSMD-based false discovery and false nondiscovery rates in genome-scale RNAi screensXiaohua Douglas Zhang, Raul Lacson, Ruojing Yang, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 6, 2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyHenry R Black, George L Bakris, Michael A Weber, et al.
Pageof 5